Synergy Asset Management LLC Purchases Shares of 134 Thermo Fisher Scientific Inc. (NYSE:TMO)

Synergy Asset Management LLC acquired a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 134 shares of the medical research company’s stock, valued at approximately $70,000.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Strategic Planning Group LLC grew its stake in Thermo Fisher Scientific by 4.5% in the fourth quarter. Strategic Planning Group LLC now owns 6,615 shares of the medical research company’s stock valued at $3,441,000 after purchasing an additional 286 shares in the last quarter. Highland Capital Management LLC grew its stake in shares of Thermo Fisher Scientific by 10.0% in the fourth quarter. Highland Capital Management LLC now owns 33,979 shares of the medical research company’s stock valued at $17,677,000 after buying an additional 3,102 shares in the last quarter. Summa Corp. lifted its stake in Thermo Fisher Scientific by 7.4% in the fourth quarter. Summa Corp. now owns 1,456 shares of the medical research company’s stock valued at $757,000 after acquiring an additional 100 shares during the last quarter. Manning & Napier Advisors LLC grew its position in shares of Thermo Fisher Scientific by 37.9% in the 4th quarter. Manning & Napier Advisors LLC now owns 267,602 shares of the medical research company’s stock valued at $139,215,000 after acquiring an additional 73,575 shares during the period. Finally, VanderPol Investments L.L.C. raised its holdings in shares of Thermo Fisher Scientific by 7.7% in the 4th quarter. VanderPol Investments L.L.C. now owns 390 shares of the medical research company’s stock valued at $203,000 after purchasing an additional 28 shares during the period. Institutional investors own 89.23% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Redburn Atlantic initiated coverage on Thermo Fisher Scientific in a research report on Monday, October 14th. They set a “buy” rating and a $680.00 price target on the stock. Scotiabank assumed coverage on Thermo Fisher Scientific in a report on Monday, December 23rd. They set a “sector perform” rating and a $605.00 price target for the company. Sanford C. Bernstein raised shares of Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 price objective on the stock in a research report on Friday, January 10th. StockNews.com upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Tuesday, January 14th. Finally, Robert W. Baird reduced their price objective on Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. Four research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $648.95.

Insider Buying and Selling

In other news, CEO Marc N. Casper sold 9,000 shares of Thermo Fisher Scientific stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $552.86, for a total transaction of $4,975,740.00. Following the sale, the chief executive officer now directly owns 14,608 shares of the company’s stock, valued at approximately $8,076,178.88. This trade represents a 38.12 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders have sold 29,000 shares of company stock worth $15,859,540 in the last 90 days. Insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Trading Up 6.8 %

Shares of TMO opened at $607.06 on Friday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.26 and a current ratio of 1.63. Thermo Fisher Scientific Inc. has a 52-week low of $493.30 and a 52-week high of $627.88. The firm has a market cap of $232.20 billion, a price-to-earnings ratio of 38.06, a PEG ratio of 3.89 and a beta of 0.76. The business’s fifty day moving average is $537.83 and its 200-day moving average is $570.33.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, topping analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. Equities analysts anticipate that Thermo Fisher Scientific Inc. will post 21.69 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, January 15th. Stockholders of record on Friday, December 13th were paid a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.26%. The ex-dividend date of this dividend was Friday, December 13th. Thermo Fisher Scientific’s payout ratio is 9.78%.

Thermo Fisher Scientific declared that its Board of Directors has initiated a stock buyback plan on Friday, November 15th that allows the company to repurchase $4.00 billion in shares. This repurchase authorization allows the medical research company to purchase up to 2% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s board believes its stock is undervalued.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.